Clover Health Investments Corp. Cl A (CLOV): Price and Financial Metrics


Clover Health Investments Corp. Cl A (CLOV): $12.04

-0.52 (-4.14%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

CLOV Stock Price Chart Interactive Chart >

Price chart for CLOV

CLOV Price/Volume Stats

Current price $12.04 52-week high $28.85
Prev. close $12.56 52-week low $6.31
Day low $12.02 Volume 34,165,200
Day high $13.45 Avg. volume 35,102,188
50-day MA $9.52 Dividend yield N/A
200-day MA $10.76 Market Cap 4.91B

Clover Health Investments Corp. Cl A (CLOV) Company Bio


Clover Health Investments, Corp. provides health insurance services. The company was founded in 2012 and is based in Franklin, Tennessee.


CLOV Latest News Stream


Event/Time News Detail
Loading, please wait...

CLOV Latest Social Stream


Loading social stream, please wait...

View Full CLOV Social Stream

Latest CLOV News From Around the Web

Below are the latest news stories about Clover Health Investments Corp that investors may wish to consider to help them evaluate CLOV as an investment opportunity.

'In the streaming world, local television simply doesn’t exist': CEO of MNTN

Mark Douglas, CEO of MNTN, joined Yahoo Finance Live to break down the outlook on the media industry.

Yahoo | June 17, 2021

Influencers with Andy Serwer: David Ricks

In this episode of Influencers, Eli Lilly Chairman & CEO David Ricks joins Andy to discuss the latest in the pharmaceutical industry, new progress in the fight against COVID-19, and potential groundbreaking advancements for the treatment of Alzheimer’s.

Yahoo | June 17, 2021

By next summer we'll have enough vaccines to vaccinate the world: Eli Lilly CEO

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss progress in the fight against COVID-19.

Yahoo | June 17, 2021

Replay: “SPAC to the Future 2” with Gallagher, Stifel, Nasdaq, ICR, MorganFranklin, V&E Featuring Hennessy, Bespoke, SOAC

If 2020 was the “Year of the SPAC,” 2021 might become known as “The SPAC Pullback.” Despite some recent signs of renewed investor interest, SPAC preparedness in the current environment is more important than ever, along with strategies for managing D&O and other insurance costs. Pre-revenue companies in particular going public via SPAC face greater […]

Yahoo | June 16, 2021

FDA ‘shifting the bar’ for approval with new Alzheimer’s drug: Eli Lilly CEO

Eli Lilly CEO David Ricks joins 'Influencers with Andy Serwer' to discuss the FDA's approval of Biogen's new Alzheimer’s drug.

Yahoo | June 16, 2021

Read More 'CLOV' Stories Here

CLOV Price Returns

1-mo 73.74%
3-mo 36.97%
6-mo -10.48%
1-year 13.58%
3-year N/A
5-year N/A
YTD -28.21%
2020 N/A
2019 N/A
2018 N/A
2017 N/A
2016 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.9838 seconds.